SS-31 (elamipretide) is a mitochondria-targeted peptide studied for its role in reducing oxidative stress and supporting mitochondrial membrane function, with research interest spanning cardiac, muscular, and aging-related applications.
Benefits
SS-31 (also known as elamipretide, MTP-131, Bendavia) is a mitochondria-targeting peptide, believed to stabilize cardiolipin in the mitochondrial membrane and reduce toxic reactive oxygen species. Unusually for this category, it has real, multiple Phase 2/3 human trials.
Multiple Phase 2 human trials: heart failure with reduced ejection fraction (PROGRESS-HF trial, 2020), atherosclerotic renal artery stenosis during stent revascularization, and a Phase 2/3 trial plus open-label extension in Barth syndrome (a genetic mitochondrial cardiolipin disorder). Across these mitochondrial-disorder trials, elamipretide has been reported well tolerated with preliminary evidence of benefit — this is a real, if still preliminary, human evidence base, not just animal data.
Dosage
Clinical trial dosing is specific to each condition studied (IV/subcutaneous protocols varying by trial) — not a single established dose applicable to general research use. Needs its own dedicated pass to pull exact per-trial doses before publishing a specific number.
What is SS-31 researched for?+
Mitochondrial function and oxidative stress reduction, with studies spanning cardiac, muscle, and general aging-related research.
Is SS-31 FDA-approved?+
No. It has been studied in clinical trials under the name elamipretide for specific conditions, but is not broadly FDA-approved, and research-labeled product is sold outside any approved pathway.
Is SS-31 the same as MOTS-c?+
No, both are studied in the mitochondrial-health research space but are structurally distinct peptides with different proposed mechanisms.
How is it different from a general antioxidant?+
It doesn't flood your whole system — it specifically targets cardiolipin, a lipid unique to the inner mitochondrial membrane, binding there directly. That precision is the point: concentrating its effect exactly where mitochondrial damage actually happens.
Is this actually in real clinical trials?+
Yes — under the name elamipretide, it's in clinical trials for several real conditions: mitochondrial genetic disease, heart failure, acute kidney injury, and aging broadly. A notably more advanced clinical pathway than most compounds in this category.
Looking for something specific, or placing a wholesale order? Send us a DM or email.